33 results about "Charcot�Marie�Tooth disease" patented technology

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject.

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, Guillian-Barre syndrome and disorders in which myelin forming glial cells are damaged including spinal cord injuries, neuropathies and nerve injury.

The present invention relates to methods for treating Charcot-Marie-Tooth Disease (CMT) with apilimod and related compositions and methods.

The present invention relates in particular to methods of detecting predisposition to or diagnosis and / or prognosis of Charcot-Marie-Tooth (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers, which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes, assessing the responsiveness to the treatments and the efficacy of treatments in subjects having CMT or a related disorder.

The instant disclosure describes an electrophoretic procedure capable of resolving and isolating ultra high molecular weight (MW) protein aggregates from nerve tissue. The procedure is based on the use of composite agarose-polyacrylamide gel electrophoresis (CAPAGE) and resolves proteins and protein aggregates over the range of from approximately 225 kDa to approximately 30,000 kDa. Triton X-100 precipitation is used to obtain a cytoskeleton protein fraction that is subsequently resuspended and subjected to gel electrophoresis. This method demonstrates that a protein aggregate of approximately 30,000 kDa is characteristic of normal murine spinal cord tissue and that the amount of said protein aggregate is increased in spinal cord homogenate obtained from transgenic mice bearing copies of a mutant human gene characteristic of familial amyotrophic lateral sclerosis. This method for separating nerve tissue ultra high MW cytoskeleton protein aggregates can prove useful in a variety of future biophysical and pharmacological studies related to the etiologies of Charcot-Marie-Tooth disease, Alzheimer's disease, Parkinson's disease, diseases based on expansions in tandem DNA repeats, spinal muscular atrophy, Friedreich's ataxia, giant axon neuropathy, juvenile ceroid-lipofuscinosis, amyotrophic lateral sclerosis, diabetic polyneuropathy and Down's syndrome.

The present invention relates to a method for the screening of a therapeutic agent for Charcot-Marie-Tooth disease (CMT) using induced pluripotent stem cells and motor neurons differentiated therefrom. Particularly, the present inventors prepared induced pluripotent stem cells from the human fibroblasts originated from CMT patient. When the motor neurons differentiated from the said induced pluripotent stem cells are used for the screening of a therapeutic agent for Charcot-Marie-Tooth disease, the pharmaceutical effect of the therapeutic agent candidates can be easily evaluated during the screening. In addition, by the method to prepare the induced pluripotent stem cells, autologous motor neurons which are usable for the screening of a patient-specific therapeutic agent and the patient-specific treatment can be prepared.

As with many human physiological systems, issues within the central nervous system can arise for individuals leading to a variety of neurological disorders including, but not limited to, Charcot-Marie-Tooth disease, Alzheimer' disease, Parkinson's disease, multiple sclerosis, myasthenia gravis, demyelination, and axonal degeneration. However, culture devices presently provide researchers with limitations in their research. Embodiments of the invention aims to address these various limitations and allow studies, methods and screenings which cannot be performed with prior art culture devices. These include reducing manufacturing complexity, volumes of pharmaceuticals and cells required, allowing use in fields other than neurobiology, improved adhesion within the desired micro-channel regions of the devices, and increasing cell survival in cultures. Accordingly, microfluidic devices comprising a connecting chamber and micro-channel having the same depth which prevents hydrostatic pressure, end walls of the connecting chamber and micro-channel arrays having a high angle relative to the fluid flow direction for supporting culturing and topside of the connecting chamber that has been profiled in order to improve the adhesion of cells is provided.

Provided are compositions and methods for the treatment of mutant glycyl-tRNA synthetase (GlyRS)-associated diseases, such as Charcot-Marie-Tooth (CMT) diseases, and related compositions and methods for diagnostic, drug discovery, and research applications. Also provided are mutant glycyl-tRNA synthetases and uses thereof.

Methods are described for screening a subject for risk of Charcot-Marie-Tooth Disease Type 2A or for diagnosing Charcot-Marie-Tooth disease or a predisposition for developing Charcot-Marie-Tooth disease in a subject, by detecting the presence or absence of a mutation in the mitofusin gene in a biological sample collected from the subject. Methods are also described for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 2A in a sample of patient nucleic acid, by amplifying a mitofusin gene sequence in the patient nucleic acid to produce an amplification product; and identifying the presence of a Charcot-Marie-Tooth Disease Type 2A associated polymorphism in the amplification product.

The invention broadly relates to the use of the Active in the causal treatment of a disease caused by axonal demyelination, in which the Active maintains the integrity of myelination (for example by promoting remyelination, and / or preventing demyelination, of the axonal sheaths). The invention is particularly directed to the causal treatment of CNS demyelination diseases, for example MS, especially primary progressive MS and / or relapse remitting MS, and PNS demyelination diseases, for example Charcot-Marie-Tooth Disease. The Active of the invention may be suitably administered when a patient is in relapse (i.e. upon relapse), and be continued while the patient is in relapse, with a view to attenuating the severity of the relapse, and / or accelerating disease remission. Alternatively, the Active may be administered continuously with a view to prolonging the remission period, and / or attenuating the severity of the relapse, and / or preventing relapse. The invention also relates to the use of the Active as a treatment for symptoms of demyelination disease, especially MS, selected from vision deficits, motor control deficits, and sensation deficits.

The invention discloses a detection kit for charcot marie tooth disease related PMP22 gene copy number variation. The detection kit comprises a 10*PCR buffer solution, a 4*GC solution, a PCR primer mixed solution, TaqDNA polymerase, a probe primer mixed solution, a DNA diluent, a 10*Taq connecting buffer solution, Taq ligase, 20m MEDTA, dNTP (2.5mM) and MgCl2 (25mM). The kit and the system for detecting PMP22 gene copy number variation on the basis of a CNVplex-high flux connecting probe amplification technology (HLPA) disclosed by the invention are mainly used for detecting the charcot marietooth disease caused by the PMP22 gene deletion or repeated mutation so as to acquire the correct copy number of each target locus of the PMP22 gene. The detection kit has the advantages of quick detection, high accuracy, high repeatability, high resolution ratio, and the like.

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signalling and thyroid hormone pathway in a subject.

The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected. The selected mouse was confirmed to display Charcot-Marie-Tooth disease phenotype, so that the animal model was expected to be efficiently used for the evaluation of the effect of Charcot-Marie-Tooth disease treating material candidates.

The invention discloses an AMSH gene mutant and an application thereof, and concretely relates to isolated nucleic acid for coding the AMSH mutant, isolated nucleic acid, a method for screening a biological sample predisposed to charcot-marie-tooth disease, a system for screening the biological sample predisposed to charcot-marie-tooth disease, and a kit used for screening the biological sample predisposed to charcot-marie-tooth disease. Compared with SEQ ID NO:1, the isolated nucleic acid for coding the AMSH mutant comprises c.364A>G mutation. By detecting whether the new mutant exists in the biological sample or not, whether the biological sample is predisposed to charcot-marie-tooth disease or not can be effectively detected.

A method of treating Charcot Marie Tooth Disease in a human in need thereof. The method comprises systemically administering to the human a non-antibacterial tetracycline compound or antibacterial tetracycline compound, in an amount that is effective to treat Charcot Marie Tooth Disease but has substantially no antibacterial activity.

Disclosed is a method for diagnosing Charcot-Marie-Tooth (CMT) disease. More specifically, disclosed is a method for diagnosing a subtype of Charcot-Marie-Tooth disease type 1, (i.e., CMT1A) and a subtype of the disease type 2 (i.e., CMT2A) by evaluating fatty infiltration behaviors in respective compartments of proximal lower extremity muscles via comparison and analysis of MRI on the proximal lower extremities. Further disclosed is a method for diagnosing CMT1A and CMT2A, by analyzing fatty infiltration levels between respective compartments by MRI examination on distal lower extremity muscles.

The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.